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Hepatitis B virus (HBV) infection is a major
global health problem. Chronically infected
people are at risk for progressive hepatic
fibrosis and consequent cirrhosis. Hepatitis B
surface antigen (HBsAg) level in serum is a
complementary marker for intrahepatic HBV
DNA and covalently closed circular DNA
(cccDNA). Sortilin-1 (SORT1) has been reported
to be involved in the post-Golgi vesicle traffick-
ing of Apo lipoproteins degradation pathways.
This study was designed to evaluate the hep-
atic and serum expression of HBsAg and its
association with hepatic SORT1 gene expres-
sion in patients with chronic HBV. Thirty
chronic hepatitis B patients with histological
examination results were enrolled in this
study. Liver biopsies were analyzed for hepatic
HBsAg and SORT1 gene expression by immu-
nohistochemistry and quantitative real time
PCR (qRT-PCR), respectively. Twenty seven out
of 30 (90%) liver biopsies had positive staining
for HBsAg and showed a significant inverse
association with hepatic SORT1 fold change
gene expression (b¼0.5, P¼ 0.042). There
was significant association between HBV DNA
levels and HBsAg expression in hepatocyte or
serum titer of HBsAg (r¼ 0.39, P¼ 0.029;
r¼ 0.39, P¼ 0.032 respectively). Serum ALT
was also correlated with hepatic activity index
(HAI) score (b¼ 0.6, P¼ 0.001). Inverse associa-
tion between hepatic SORT1 gene expression
and hepatic HBsAg expression indicates the
possible role of sortilin in HBsAg particle
formation. J. Med. Virol.
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INTRODUCTION
Chronic active hepatitis B patients characterized
by high or fluctuating liver transaminases and/or
HBV DNA levels are at great risk for subsequent
development of chronic liver disease, including cir-
rhosis and hepatocellular carcinoma (HCC) [Wang
et al., 2008; Mohamadkhani et al., 2010]. Hepatitis B
surface antigen (HBsAg) positivity in serum is the
hallmark for the diagnosis of chronic hepatitis B
virus infection. Studying the membrane structure of
HBsAg particles by fluorescence correlation spectro-
scopy (FCS) demonstrated that the HBsAg particles,
like low density lipoproteins (LDLs), exhibit a lip-
oprotein-like structure in which a phospholipid mono-
layer surrounds a more hydrophobic inner core, likely
composed of 40% lipids including sterol esters, trigly-
cerides, and fatty acids [Diminsky et al., 1997;
Greiner et al., 2010]. Therefore, it is probable that
lipids metabolism affect the structure and the expo-
sure of specific epitopes and immunogenicity of HBV
[Satoh et al., 2000; Mohamadkhani et al., 2012].
The protein sortilin is a multi-ligand type-1 recep-
tor and a member of vacuolar protein sorting 10
protein (VPS10P) domain receptor family that has
been identified in association with LDL-C levels in
humans [Willnow et al., 2011; Strong et al., 2012].
The gene encoding human sortilin, SORT1, consists
of 22 exons that maps on the short arm of
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chromosome 1 (1p21.3-p13.1) [Musunuru et al.,
2010]. The subcellular localisation of SORT1 limits
mainly to the Golgi apparatus and attaches to a
variety of ligands on its extracellular VPS10 domain
to transport them to the lysosome then back to the
Golgi by the retromer complex [Strong and Rader,
2012]. Recent studies have suggested SORT1 in
lipoproteins metabolism in the liver and adipose
tissue [Dube et al., 2011]. Indeed, genome wide
association studies (GWAS) in human have shown a
strong association of a specific SNP in the SORT1
gene with increase in SORT1 hepatic expression and
considerable decreased serum levels of LDL and
coronary heart disease [Musunuru et al., 2010;
Strong et al., 2012]. On the other hand higher
activity of mTORC1 in obese mice enhance secretion
of Apo B, a main principal protein in lipoproteins and
their metabolism, by reducing hepatic Sort1
[Ai et al., 2012]. Moreover Strong et al., presented
that hepatic sortilin both decreases hepatic APOB
secretion and reduce the catabolism of LDL [Willnow
et al., 2011; Strong et al., 2012].
As sortilin binds a number of ligands and partic-
ipates in a wide range of cellular processes and
regarding to the lipoprotein-like structure of HBsAg
particles, we hypothesized for a probable role of
sortilin in intracellular trafficking of HBsAg and
consequently its effect on concentration of hepatic
and serum HBsAg. The assumed association of
SORT-1 gene expression and intracellular sortilin
levels has been previously studied [Strong et al.,
2012; Ghaemimanesh et al., 2014]. Therefore, the
main objective of this study was to evaluate hepatic
and serum expression of HBsAg and its association
with hepatic SORT1 gene expression in patients with
chronic HBV.
PATIENTS AND METHODS
Study Population
Thirty patients with e-antigen negative chronic
hepatitis B (73% (n¼ 22) male) referred to Shariati
Hospital, Tehran University of Medical Sciences from
Jan 2009 to Jan 2011, were enrolled in this study.
Patients had no evidence of other liver diseases such
as hepatitis C and autoimmune hepatitis. Demo-
graphic data and blood samples were collected at the
initial assessment (first visit). Serum samples were
stored at 70˚C prior to analysis. Formalin-fixed
paraffin-embedded liver biopsies from these HBeAg
negative patients were used in this study. Biopsies
were either performed for therapeutic purposes or as a
part of a protocol with the objective of evaluating
response to therapy after 2 years of lamivudine
therapy. Patients with a HBV viral load of more than
2000 IU/ml and significant (moderate-severe) necroin-
flammation and/or at least moderate fibrosis, on biopsy
(n¼ 14) were considered for antiviral treatment after
liver biopsy. None of the patients received (antiviral)
treatment prior to liver biopsy. Formalin-fixed
paraffin-embedded of three specimens with no histo-
logical liver abnormalities were used as control sam-
ples. All patients or their legal representatives signed
an informed consent according to the ethical guidelines
of the 1975 Declaration of Helsinki and its subsequent
1983 revision prior to blood sample collection. The
study protocol was approved by the Ethics Committee
of the Digestive Disease Research Institute, Tehran
University of Medical Sciences.
Quantification of HBsAg and HBV DNA in Serum
HBV DNA levels in serum samples were quantified
by LightCycler v 3.5 (Roche Applied Science, Man-
nheim, Germany) using the RealARTTM HBV LC
PCR (QIAGEN, Hilden, Germany) with a detection
limit of 10 IU/ml according to the manufacturer’s
instructions.. HBsAg titers were determined with the
Architect HBs-Antigen QT assay (Abbott Laborato-
ries, Wiesbaden, Germany) based on an automated
chemiluminescent microparticle immunoassay, follow-
ing the manufacturer’s recommendation. The Archi-
tect HBsAntigen QT assay measures a range of
HBsAg from 0.05 to 250 IU/ml. Therefore, all samples
were primarily tested at dilutions of 1 in 1000 within
Architect HBsAg Manual Diluent.
Liver Biopsies Examination and
Immunohistochemical Staining
Liver biopsies from all patients were evaluated for
histological activity index (HAI); rating necroinflam-
mation with a score between 0–18, and fibrosis stage
using Ishak’s scoring system; rating fibrosis with a
score between 0–6. The presence of steatosis was
considered as negative or positive. Deparaffinized
sections were stained with mouse anti human mono-
clonal antibody against HBsAg (dilution 1/20, clone
3E7, Dako, Carpinteria, CA) to evaluate the level and
pattern of HBsAg expression in the hepatocytes. The
staining was developed with standard avidin-biotin
peroxidase method (Vectastain Elite ABC kit; Vector
Laboratories, Burlingame, CA). The immunohisto-
chemical staining for HBsAg was quantified visually.
The number of HBsAgþ cells in the parenchymal
area was counted in 10 low power fields and the
results were reported by IHC score as a percentage of
the overall parenchymal area; 0¼ absent, þ1< 25%,
þ2¼ 25–50%, þ3¼ 50–75%, and þ4> 75%. The stain-
ing results were separately evaluated by two gastro-
intestinal pathologists who were blinded to the
clinical information.
RNA Extraction and Real-Time PCR
Total liver RNA was extracted from four 20mm
sections from formalin fixed paraffin embedded tissue
using RNeasy FFPE Kit (Qiagen, country) according to
the manufacturer’s instructions. The concentration of
purified RNA sample was measured by NanoDrop
ND-1000TM (Nanodrop Technologies) spectrophotometer.
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To synthesis cDNA, 5mg of total RNA was used in 20mL
reaction mixture of Sensiscript1 Reverse Transcription
Kit (QIAGEN, Hilden, Germany), incubated at 42˚C for
45min and stored at 20˚C until use. The housekeeping
gene b-actin was used for the normalization of qPCR
SORT1 gene. The specific primer pairs used were precise
primers of “50-CAGTCCAAGCTATATCGAAGTGAGG-30”
as forwards and “50-AAGATGGTGTTGTCTGATCCC-
CATTT-30” as reverse for SORT1 and “50-
CTGGAACGGTGAAGGTGACA-30” as forward and
“50-AAGGGACTTCCTGTAACAATGCA-30” as reverse
primers for b-actin (Operon, K€oln, Germany).
A light Cycler1 FastStart DNA MasterPLUS SYBR
Green I (QIAGENHilden, Germany) reaction was
performed on Roche light cycler version 3.5 according
to the manufacturer’s protocol. PCR amplification for
both SORT1 and b-actin was conducted for 40 cycles
with the following conditions: denaturation for 30 sec
at 95˚C, annealing for 30 sec at 60˚C, and extension
for 1min at 70˚C. The expression level of SORT1 was
normalized to the b-actin. Relative Quantification
(RQ), which defines the fold change or how much the
gene is differentially expressed, was calculated using
the comparative CT method (2DDCT) [Pfaffl, 2001;
Spinsanti et al., 2008].
Statistical Analysis
Variables were expressed as mean ( standard
deviation), and number (percentage) where appropri-
ate. The HBsAg and HBV-DNA levels were logarith-
mically transformed for statistical analyses.
Multivariate logistic regression analysis was used to
identify the predictor for hepatic sortilin expression
and all variables with P-value of less than 0.5 in
univariate analysis were entered into multivariate
analysis. The statistical analysis was performed
using the SPSS software (version 19; SPSS, Chicago,
IL). P value of less than 0.05 was considered
significant.
RESULTS
Characterization of the Study Population
There were a total of 30 HBsAg positive patients
with mean (SD) age of 34 ( 9) years. The mean
(SD) of log10 of serum HBV DNA was 3.39 ( 1.33)
IU/ml. Male to female ratio was 2.8 (22 males and 8
females). Demographic characteristics of these pa-
tients along with the biochemical profiles are sum-
marized in Table I.
Histological Findings and Their Correlation
With Clinical Variables
HBsAg immunohistochemical staining was positive
in 27 (90%) of the patients with focal or diffuse
cytoplasmic pattern (Fig. 1). Histological examination
showed a mean (SD) of 1.8 1.3 and 4.6 2.0 for
fibrosis stage and total HAI score respectively. To
study the factors associated with liver fibrosis,
patients were divided into two groups according to
the stage of fibrosis. Patients with a stage of 0–2
were defined as low fibrosis while those with a score
above 2 were defined as high fibrosis. No significant
differences were seen with respect to the mean of
age, log 10HBV DNA, HBsAg titre, serum cholesterol,
triglyceride, LDL, and sortilin fold change between
high and low fibrosis groups (Table II). There was a
significant association between serum ALT levels and
liver HAI score (b¼ 0.6, P¼ 0.001) and patients with
greater fibrosis stage had higher levels of serum ALT
compared to lower fibrosis stage (63 41 vs.
38 15 IU/ml, P¼ 0.02). The association between
serum ALT levels and HAI score remained significant
after adjustment for Log 10HBV DNA, cholesterol,
SORT1 fold change and HBsAg expression score in a
multivariate analysis.
Univariate analysis revealed no significant associa-
tion between the presence of steatosis with gender,
age, SORT1 fold change, HBsAg level, cholesterol
and triglyceride levels. Serum HBV DNA level was
significantly correlated with serum HBsAg levels
(r¼ 0.39, P¼ 0.032) and hepatic expression of HBsAg
(r¼ 0.39, P¼ 0.029). Furthermore, we found a corre-
lation between serum HBV DNA and cholesterol
levels (r¼ 0.36, P¼ 0.045
Factors Associated With Sortilin Expression
Univariate analysis of all variables (age, gender,
HBV viral load, serum ALT, HAI score, cholestrol,
triglycerides, LDL, HBsAg expression score (in hepato-
cytes) and serum HBsAg titer), showed a significant
inverse association between SORT1 fold change and
hepatic HBsAg expression (b¼0.42, P-value¼ 0.022)
(Fig. 2). In multivariate analysis, we adjusted for all
variables with a P< 0.5, except serum HBsAg titer due
to the correlation with HBsAg expression IHC score.
This inverse association was seen again between
hepatic HBsAg expression and SORT1 fold changes
(b¼0.5, P¼ 0.042), (Table III).
TABLE I. Summary of Clinical Characterization of Chronic
Patients With HBV Infection
Variables Mean (SD)
Age (years) 34 ( 9.6)
Log 10HBV DNA (IU/ml) 3.39 ( 1.33)
ALT (IU/L) 46 ( 27)
HAI score 4.6 ( 2.0)
Histological fibrosis score 1.8 ( 1.3)
Quantitative HBsAg titer (IU/ml) 5062 ( 8854)
Cholestrol (mg/dL) 203 ( 45)
LDL(mg/dL) 122 ( 31)
Triglycerides(mg/dL) 124 ( 57)
SORT-1 fold changes 2.7 ( 2.1)
Liver HBS Ag expression score (IHC) 1.7 ( 1.1)
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DISCUSSION
We showed that higher expression of hepatic
SORT1 in patients with chronic hepatitis B is
associated with decreased levels of HBsAg in hepato-
cytes. In addition, we found a correlation between
hepatic expression of HBsAg and levels of serum
HBV DNA in accordance with previous studies
[Brunetto et al., 2010; Su et al., 2010].
Hepatic HBsAg with a typical ground-glass form in
hepatocytes is a marker of HBV infection as well as
source of sub-viral particles in circulation. The ex-
pression pattern of these particles is influenced by
the natural course of chronic hepatitis in patients
with HBeAg-positive [Hsu et al., 1988; Wang et al.,
2003]. Several studies have shown a positive correla-
tion between serum HBsAg and HBV DNA, therefore
serum HBsAg titer could be a surrogate marker of
intrahepatic HBV DNA and cccDNA [Su et al., 2010;
Tseng et al., 2011].
Persistent HBsAg production independent of viral
load indicates that viral DNA could integrate into the
host chromosomes in the course of infection and
provide a template for HBsAg transcription [Wang
et al., 2003]. The synthesis of HBsAg occurs at the
endoplasmic reticulum more than necessary. Inter-
molecular disulphide bonds within extra particles
produce and secret non-infectious filamentous or
spherical particles into the peripheral circulation.
The lipoprotein structure of HBsAg particles is
composed of host-derived lipids and virus encoded
glycoproteins. These particles exhibit a lipoprotein-
like structure in which a compact phospholipid mono-
layer surrounds a more hydrophobic and fluid inner
core, likely composed of triglycerides, fatty acids and
sterol esters [Satoh et al., 2000; Greiner et al., 2010].
Quantification of HBsAg is important to refine
treatment algorithms. In this way many viable
assays can detect as little as a few nanograms of
HBsAg per milliliter of serum [Satoh et al., 2000; Su
et al., 2010]. HBsAg quantification detects all three
forms of systemic HBsAg (part of HBV virion,
spherical, filamentous), differentiation between the
relative proportions is currently not routine. Most of
chronic patients has HBsAg titers greater than 1mg
per ml of blood and could play a role to paralyses the
host immune response [Satoh et al., 2000; Greiner
et al., 2010]. Therefore, reducing production of
HBsAg represents a step forward to future successful
immune response and HBsAb seroconversion. It has
Fig. 1. Hepatic HBsAg expression shows both cytoplasmic and membranous pattern
(magnification x100) in first row, (magnification x400) in second row.
TABLE II. Comparison of Demographic, Biochemical and Virologic Characteristics Between Patients With Low and High
Fibrosis
Fibrosis
#
patient Age
log10 HBV
DNA ALT
Quantitative
HBsAg (IU/ml) Chol LDL TG
SORT-1
fold change
HBsAg
score
Low 21 34  10 3.14  1.29 38  15 4289  9110 200  46 121  31 118  40 2.90  2.36 1.6  1.2
High 9 34  9 3.98  1.29 63  41 6866  8451 209  43 124  33 137  87 2.22  1.56 2.0  1.0
P value 0.8 0.9 0.02 0.4 0.6 0.7 0.4 0.4 0.4
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been demonstrated that decreased levels of serum
HBsAg in adult chronic hepatitis B patients indicate
for favorable outcomes [Tseng et al., 2011].
The comparable structure of HBsAg and LDL
suggest that factors involving lipid metabolism would
be valuable in researching the hepatitis B virus life
cycle and mechanisms for HBsAg degradation. It is
well known that posttranslational presecretory degra-
dation of hepatic lipoproteins is regulated via both
proteasomal-dependent and lysosomal-dependent
pathways. Sortilin-1 promotes trafficking of ApoB-
containing lipoproteins into intracellular, possibly
lysosomal, degradation pathways [Strong et al.,
2012]. These findings are suggestive of the clinical
status/importance of hepatic sortilin in the manage-
ment of CHB patients. Therefore, we hypothesized
that sortilin can act as a sorting receptor to bind
intracellular HBsAg and trafficking them to degrada-
tion pathways. Although we could not find any
association between SORT1 gene expression and
Fig. 2. Scatter plot of correlation between hepatic SORT-1 fold change and HBsAg expression
score.
TABLE III. Linear Regression Model of Factors Related to the SORT-1 Folds Changes in Cases of Chronic Hepatitis B
Variables
Univariate Multivariate
Unstandardized b P Standardized b P
Age(year) 0.2 0.3 0.2 0.3
Gender 0.16 0.4 0.002 1
Male (reference)
Female
Viral load (IU/ml) 0.23 0.2 0.02 1
ALT (IU/ml) 0.06 0.8 – –
HAI score 0.2 0.4 0.1 0.6
Cholesterol(mg/dL) 0.2 0.3 0.3 0.6
LDL(mg/dL) 0.2 0.3 0.4 0.3
TG(mg/dL) 0.04 0.9 – –
HBsAg titer 0.33 0.07 – –
HBsAg expression score 0.42 0.02 0.5 0.04
Mean  SD.
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serum LDL levels probably because of low sample
size, however, we further demonstrated that hepatic
sortilin is inversely associated with HBsAg expres-
sion in hepatocytes. To investigate the potential
underlying mechanisms of sortilin in reducing HBsAg
levels metabolic features of host cells infected with
HBV need to be characterized. Future studies with
sufficient numbers of both HBeAg negative and
HbeAgpositive patients should be performed for vali-
dation of our findings.
In conclusion, we found, for the first time, an
inverse association between hepatic SORT1gene ex-
pression and hepatic HBsAg expression suggestive of
the possible role of sortilin in HBsAg metabolism.
Hepatic sortilin could be proposed as potential factor
in reducing HBsAg levels in chronic hepatitis.
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